Is Mereo BioPharma Group plc (MREO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 10.3% / 30% | 111.3% / 30% | 5.2% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 10.3% / 33% | 111.3% / 33% | 5.2% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 8.4% / 33% | 91.4% / 33% | 4.3% / 33% | N/A | ✗ NOT HALAL |
| S&P | 10.3% / 33% | 111.3% / 33% | 5.2% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 8.4% / 33% | 91.4% / 33% | 4.3% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 73.4% | |
| Operating Margin | -7711.4% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -82.2% | |
| Return on Assets (ROA) | -39.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$33M |
| Free Cash Flow | -$34M |
| Total Debt | $6M |
| Debt-to-Equity | 0.5 |
| Current Ratio | 10.5 |
| Total Assets | $76M |
Price & Trading
| Last Close | $0.34 |
| 50-Day MA | $0.42 |
| 200-Day MA | $1.51 |
| Avg Volume | 15.3M |
| Beta | 0.3 |
|
52-Week Range
$0.20
| |
About Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Mereo BioPharma Group plc (MREO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Mereo BioPharma Group plc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Mereo BioPharma Group plc's debt ratio?
Mereo BioPharma Group plc's debt ratio is 10.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 8.4%.
What are Mereo BioPharma Group plc's key financial metrics?
Mereo BioPharma Group plc has a market capitalization of $53M. Return on equity stands at -82.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.